SARS-CoV-2: big seroprevalence data from Pakistan—is herd immunity at hand?

Purpose Seroprevalence surveys from different countries have reported SARS CoV-2 antibodies below 20% even in the most adversely affected areas and herd immunity cannot be predicted till more than half of the population gets the disease. The purpose of this survey was to estimate the magnitude of co...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Infection 2021-10, Vol.49 (5), p.983-988
Hauptverfasser: Haq, Mohsina, Rehman, Asif, Ahmad, Junaid, Zafar, Usman, Ahmed, Sufyan, Khan, Mumtaz Ali, Naveed, Asif, Rajab, Hala, Muhammad, Fawad, Naushad, Wasifa, Aman, Muhammad, Rehman, Hafeez Ur, Ahmad, Sajjad, Anwar, Saeed, Haq, Najib Ul
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose Seroprevalence surveys from different countries have reported SARS CoV-2 antibodies below 20% even in the most adversely affected areas and herd immunity cannot be predicted till more than half of the population gets the disease. The purpose of this survey was to estimate the magnitude of community-based spread of the infection, associated immunity, and the future prospects and proximity to a ‘herd community’. Methods The study was undertaken as a cluster randomized, cross-sectional countrywide survey. This largest community-based seroprevalence data of SARS-CoV-2 were collected between 15th and 31st July, 2020 from seven randomly selected cities belonging to the three most populous provinces of Pakistan. The FDA approved kit of ROCHE was used for detection of SARS-CoV-2 antibodies. Results Serum samples of 15,390 participants were tested for SARS CoV-2 antibodies with an overall seroprevalence of 42.4%. The seroprevalence ranged from 31.1% to 48.1% in different cities with the highest in Punjab province (44.5%). In univariable analysis, the odds of seropositivity was higher in men compared to women (OR: 1.10, 95% CI: 1.01–1.19, P  
ISSN:0300-8126
1439-0973
DOI:10.1007/s15010-021-01629-2